Healio (4/27, Gramigna) reports that even though “substance use is less prevalent among pregnant women than nonpregnant women, use during pregnancy has significant adverse effects on maternal, as well as fetal, neonatal and childhood health outcomes, according to” a presentation given by Kimberly Yonkers, MD, director of psychological medicine and the Center for Wellbeing of Women and Mothers at Yale School of Medicine, at the American Psychiatric Association Spring Highlights Meeting. In addition, “the legalization of cannabis…has directly affected pregnant women, since this population has exhibited significant preconception, prenatal and postpartum prevalence rates, according to Yonkers.” Finally, “maternal nicotine use also presents significant perinatal risks, including fetal growth restriction, ectopic pregnancy, placental disorders and fetal or infant death, Yonkers said.”
Related Links:
— “The landscape of perinatal substance use: Prevalence, outcomes and interventions, “Joe Gramigna, Healio, April 27, 2020